Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
We've identified companies pioneering blood-based cancer testing that could fundamentally transform oncology care. These technologies enable detection of cancer's genetic signatures from simple blood draws, potentially shifting treatment from late-stage intervention to early detection when outcomes are better and costs are lower.
What You Need to Know
This collection offers growth potential by targeting the expanding medical diagnostics sector. Companies range from established market leaders to promising biotech innovators. The sector is gaining momentum as regulatory approvals increase and insurance companies expand coverage, validating these technologies.
Why These Stocks
These companies were handpicked based on their leadership in developing non-invasive cancer diagnostics, commercial success of existing products, or promising late-stage clinical pipelines. Each represents a strategic position in the evolution toward blood-based testing that could redefine cancer screening and monitoring.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+204.34%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 204.34% over the next year.
Stocks Rated Buy by Analysts
11 of 14 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Medical Breakthrough Potential
These companies are developing technology that could revolutionize how we detect and monitor cancer. Early detection means better outcomes, creating both healthcare impact and significant profit potential.
Simple Blood Test, Massive Market
Imagine detecting cancer with just a routine blood draw. This simplicity is driving rapid adoption that could capture billions from traditional diagnostic methods and create entirely new screening markets.
Regulatory Momentum Building
FDA approvals and insurance coverage are accelerating for these technologies. Each new approval can trigger significant stock movements as companies transition from research phase to commercial revenue growth.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.